HK inno.N, a leading South Korean pharmaceutical company that specializes in developing and manufacturing pharmaceutical products, is currently grappling with a crucial decision regarding its highly successful gastroesophageal reflux disease treatment, 'K-CAB.' Having penetrated a prescription market valued at around $74 million, the firm is now standing at a pivotal crossroads. It must determine whether to seek a new partner for co-promotion, as its contract with current partner, Chong Kun Dang, approaches its expiration this year. Multiple contenders within the South Korean pharmaceutical industry have extended offers for K-CAB sales, fueling speculation about the impending partnership decision.

Sources within the industry, as of September 19th, reveal that HK inno.N has been actively exploring potential co-promotion partners for 'K-CAB,' which includes the active ingredient tegoprazan. Several pharmaceutical companies have reportedly submitted co-promotion proposals to HK inno.N thus far. Based on the evaluations of these proposals, HK inno.N intends to announce its decision regarding K-CAB's future partner during the fourth quarter.

K-CAB made a significant impact in the market, achieving a prescription drug market size of $88 million, as per data from research firm UBIST from the previous year. It represents a pioneering potassium-competitive acid blocker (P-CAB) medication, the first of its kind to be introduced in South Korea. K-CAB has gained recognition for its effective expansion of indications, challenging the market dominance previously held by proton pump inhibitors (PPIs) in the treatment of conditions such as gastroesophageal reflux disease and digestive ulcers. Some analysts attribute its success, in part, to the co-promotion partnership with Chong Kun Dang.

In January 2019, HK inno.N inked a co-promotion agreement with Chong Kun Dang, merely six months after the launch of the product, K-CAB. The agreement entailed Chong Kun Dang managing market distribution, while both companies operated in their designated areas of expertise. Chong Kun Dang, a formidable player in the gastrointestinal drug sector and a top-tier firm in South Korean sales, was perceived as a strategic partner capable of capitalizing on K-CAB's growth potential throughout the co-promotion period.

The co-promotion strategy undeniably yielded positive results. In 2022, K-CAB achieved prescription sales exceeding $74 million, according to UBIST, while IQVIA reported revenue exceeding $74 million starting from 2021. K-CAB maintained its impressive growth trajectory. Nevertheless, within both firms, some concerns lingered.

One concern revolved around the marketing rights for the "oral disintegrating tablet" version of the medication. K-CAB aimed to broaden its market presence by introducing the oral disintegrating tablet alongside the existing tablet formulation in May 2022. However, there was no co-promotion agreement in place for the oral disintegrating tablet. Discussions took place within Chong Kun Dang regarding the necessity of marketing efforts to maximize the impact, emphasizing the significance of promoting the oral disintegrating tablet. Nonetheless, the co-promotion contract exclusively covered K-CAB tablets, leaving Chong Kun Dang unable to engage in marketing activities for the K-CAB oral disintegrating tablet.

HK inno.N, too, had its own set of concerns. One issue that surfaced pertained to the commission fees associated with co-promotion. While exact figures are challenging to pin down, even when considering K-CAB as a new drug, it had one of the highest co-promotion commission rates among South Korean products. Furthermore, whispers circulated in some circles suggesting that Chong Kun Dang, already possessing a strong presence in the PPI market, might prioritize its own high-margin products over K-CAB.

However, HK inno.N needed to carefully weigh the pros and cons of adhering to the existing arrangement versus exploring new avenues. Chong Kun Dang's robust South Korean sales network and its commendable track record in promoting K-CAB within critical healthcare institutions underscored its significance in the K-CAB prescription market. The scarcity of companies boasting such a formidable sales force made this a crucial factor to consider.

Additionally, K-CAB faced competition from formidable players in the gastrointestinal disorders market. Daewoong Pharmaceutical actively promoted 'Fexuclue' as a competitor, while Jaeil Pharmaceutical, with its extensive sales network, awaited approval for 'JP-1366,' a new P-CAB-based medication currently under development by its subsidiary Onconic Therapeutics.

Within the pharmaceutical industry, the consensus suggests that K-CAB's co-promotion partnership hinges on two pivotal factors: "commission fees" and "local sales capabilities." Identifying a partner capable of striking the right balance between reducing commission fees while demonstrating robust local sales capabilities is paramount. Furthermore, the selected partner must establish a presence in local clinics, particularly for conditions related to gastroesophageal disorders, where PPIs are frequently prescribed.

These discussions within the industry have prompted speculation about potential partners. One contender is urgently seeking to expand its sales, while another possesses the potential to leverage P-CAB co-promotion. The latter had previously submitted proposals for K-CAB co-promotion in 2017, albeit maintaining multinational ties. However, established partners like Chong Kun Dang, with their proven capabilities, remain viable candidates.

When approached for comment, HK inno.N declined to disclose their position, maintaining a cloak of secrecy around their decision-making process.